PRODUCT INFORMATION



GNE-477

Item No. 27977

CAS Registry No.:	1032754-81-6	H ₂ N N
Formal Name:	5-[7-methyl-6-[[4-(methylsulfonyl)-1-	
	piperazinyl]methyl]-4-(4-morpholinyl)	
	thieno[3,2-d]pyrimidin-2-yl]-2-	
	pyrimidinamine	
MF:	$C_{21}H_{28}N_8O_3S_2$	S N
FW:	504.6	
Purity:	≥98%	
Supplied as:	A solid	
Storage:	-20°C	0 0 Ŭ
Stability:	≥4 years	0

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GNE-477 is supplied as a solid. A stock solution may be made by dissolving the GNE-477 in the solvent of choice, which should be purged with an inert gas. GNE-477 is soluble in the organic solvent DMSO.

Description

GNE-477 is a dual inhibitor of PI3K (IC₅₀ = 4 nM for PI3K α) and mTOR (apparent K_i = 21 nM).¹ It inhibits proliferation of MCF-7.1 cells with an EC_{50} value of 143 nM. It reduces tumor growth in a PC3-NCI tumor xenograft model when administered at doses ranging from 1 to 20 mg/kg per day.

Reference

1. Heffron, T.P., Berry, M., Castanedo, G., et al. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg. Med. Chem. Lett. 20(8), 2408-2411 (2010).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM